中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 568-572

Clinical significance of determining the level of biliary calprotectin in patients with cholangiocarcinoma or choledocholithiasis

DOI: 10.12449/JCH240321

  • Department of Gastroenterology，The First Affiliated Hospital of Anhui Medical University，Hefei 230000，China

Research funding:

Youth Project of Natural Science Foundation of Anhui Province (2008085QH415)

More Information
  • Corresponding author: MEI Qiao， meiqiaomq@aliyun.com （ORCID： 0000-0002-0635-6564）
  • Received Date: 2023-06-16
  • Accepted Date: 2023-07-14
  • Published Date: 2024-03-20
    Abstract
  •   Objective  To investigate the difference in the level of biliary calprotectin between patients with cholangiocarcinoma and those with choledocholithiasis.  Methods  Clinical data and bile samples were collected from 34 patients with cholangiocarcinoma and 78 patients with choledocholithiasis who were diagnosed and treated with endoscopic retrograde cholangiopancreatography in The First Affiliated Hospital of Anhui Medical University from May 2021 to September 2022. Fluorescence lateral flow immunoassay was used to measure the levels of calprotectin， hemoglobin， and lactoferrin in bile. The Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups； the Spearman correlation test was used for correlation analysis； the DeLong test was used for comparison of the area under the ROC curve （AUC）.  Results  Compared with the choledocholithiasis group， the cholangiocarcinoma group had significant increases in the levels of calprotectin ［4 795.50 （2 286.79‍ ‍—‍ ‍20 179.73） ng/mL vs 411.16 （67.03‍ ‍—‍ ‍1 991.88） ng/mL， Z=5.572， P<0.001］ and fluoride ［115.70 （109.10‍ — ‍125.50） mmol/L vs 106.60 （98.60‍ ‍—‍ ‍114.40） mmol/L， Z=2.702， P=0.007］. The patients with cholangiocarcinoma were further divided into high cholangiocarcinoma group and low cholangiocarcinoma group， and there was no significant difference between the two groups in the level of calprotectin ［3 867.71 （2 235.66‍ — ‍26 407.40） ng/mL vs 4 795.50 （2 361.15‍ — ‍13 070.53） ng/mL， Z=0.129， P>0.05］. Biliary calprotectin level was correlated with white blood cell count， hemoglobin concentration， and lactoferrin concentration in bile （r=0.316， 0.353， and 0.464， all P<0.05）. The ROC curve analysis showed that biliary calprotectin （with a sensitivity of 79.4% and a specificity of 75.6%）， blood CA19-9 （with a sensitivity of 82.4% and a specificity of 78.2%）， and their combination （with a sensitivity of 88.2% and a specificity of 73.1%） had good sensitivity and specificity in the diagnosis of cholangiocarcinoma.  Conclusion  There is an increase in the level of biliary calprotectin in patients with cholangiocarcinoma， and therefore， it might become a biomarker for the diagnosis of cholangiocarcinoma.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    RAGGI C, TADDEI ML, RAE C, et al. Metabolic reprogramming in cholangiocarcinoma[J]. J Hepatol, 2022, 77( 3): 849- 864. DOI: 10.1016/j.jhep.2022.04.038.
    [2]
    JANG S, STEVENS T, KOU L, et al. Efficacy of digital single-operator cholangioscopy and factors affecting its accuracy in the evaluation of indeterminate biliary stricture[J]. Gastrointest Endosc, 2020, 91( 2): 385- 393.e1. DOI: 10.1016/j.gie.2019.09.015.
    [3]
    CHEN S, WANG J. Advances in tumor microenvironment and immunotherapy of cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38( 10): 2428- 2432. DOI: 10.3969/j.issn.1001-5256.2022.10.044.

    陈顺, 王俊. 胆管癌肿瘤微环境与免疫治疗[J]. 临床肝胆病杂志, 2022, 38( 10): 2428- 2432. DOI: 10.3969/j.issn.1001-5256.2022.10.044.
    [4]
    ZUO S, CHEN Q, ZOU WL. Current status and prospect of immunotherapy for cholangiocarcinoma[J]. Chin J Dig Surg, 2022, 21( 7): 873- 879. DOI: 10.3760/cma.j.cn115610-20220506-00254.

    左石, 陈乾, 邹卫龙. 胆管癌免疫治疗的现状与展望[J]. 中华消化外科杂志, 2022, 21( 7): 873- 879. DOI: 10.3760/cma.j.cn115610-20220506-00254.
    [5]
    GIESE MA, HIND LE, HUTTENLOCHER A. Neutrophil plasticity in the tumor microenvironment[J]. Blood, 2019, 133( 20): 2159- 2167. DOI: 10.1182/blood-2018-11-844548.
    [6]
    JUKIC A, BAKIRI L, WAGNER EF, et al. Calprotectin: From biomarker to biological function[J]. Gut, 2021, 70( 10): 1978- 1988. DOI: 10.1136/gutjnl-2021-324855.
    [7]
    ARGYRIS PP, SLAMA ZM, ROSS KF, et al. Calprotectin and the initiation and progression of head and neck cancer[J]. J Dent Res, 2018, 97( 6): 674- 682. DOI: 10.1177/0022034518756330.
    [8]
    SHABANI F, FARASAT A, MAHDAVI M, et al. Calprotectin(S100A8/S100A9): A key protein between inflammation and cancer[J]. Inflamm Res, 2018, 67( 10): 801- 812. DOI: 10.1007/s00011-018-1173-4.
    [9]
    PAN SG, HU Y, HU MJ, et al. S100A8 facilitates cholangiocarcinoma metastasis via upregulation of VEGF through TLR4/NF-‍κB pathway activation[J]. Int J Oncol, 2020, 56( 1): 101- 112. DOI: 10.3892/ijo.2019.4907.
    [10]
    LIANG HJ, QIN SK, SHEN F, et al. Expert consensus on diagnosis and treatment of CSCO biliary systerm tumors(2019 edition)[J]. Chin Clin Oncol, 2019, 24( 9): 828- 838.

    梁后杰, 秦叔逵, 沈锋, 等. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019, 24( 9): 828- 838.
    [11]
    DELONG ER, DELONG DM, CLARKE-PEARSON DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach[J]. Biometrics, 1988, 44( 3): 837- 845.
    [12]
    KHAN SA, DAVIDSON BR, GOLDIN RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update[J]. Gut, 2012, 61( 12): 1657- 1669. DOI: 10.1136/gutjnl-2011-301748.
    [13]
    CAO HS, HUANG T, DAI MR, et al. Tumor microenvironment and its implications for antitumor immunity in cholangiocarcinoma: Future perspectives for novel therapies[J]. Int J Biol Sci, 2022, 18( 14): 5369- 5390. DOI: 10.7150/ijbs.73949.
    [14]
    MAO ZY, ZHU GQ, XIONG M, et al. Prognostic value of neutrophil distribution in cholangiocarcinoma[J]. World J Gastroenterol, 2015, 21( 16): 4961- 4968. DOI: 10.3748/wjg.v21.i16.4961.
    [15]
    ZHOU SL, DAI Z, ZHOU ZJ, et al. CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils[J]. Carcinogenesis, 2014, 35( 3): 597- 605. DOI: 10.1093/carcin/bgt397.
    [16]
    LI YW, QIU SJ, FAN J, et al. Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection[J]. J Hepatol, 2011, 54( 3): 497- 505. DOI: 10.1016/j.jhep.2010.07.044.
    [17]
    JENSEN HK, DONSKOV F, MARCUSSEN N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma[J]. J Clin Oncol, 2009, 27( 28): 4709- 4717. DOI: 10.1200/JCO.2008.18.9498.
    [18]
    JAILLON S, PONZETTA A, DI MITRI D, et al. Neutrophil diversity and plasticity in tumour progression and therapy[J]. Nat Rev Cancer, 2020, 20( 9): 485- 503. DOI: 10.1038/s41568-020-0281-y.
    [19]
    SHAUL ME, FRIDLENDER ZG. Tumour-associated neutrophils in patients with cancer[J]. Nat Rev Clin Oncol, 2019, 16( 10): 601- 620. DOI: 10.1038/s41571-019-0222-4.
    [20]
    VOIGTLÄNDER T, WLECKE J, NEGM AA, et al. Calprotectin in bile: A disease severity marker in patients with primary sclerosing cholangitis[J]. J Clin Gastroenterol, 2014, 48( 10): 866- 869. DOI: 10.1097/MCG.0000000000000042.
    [21]
    GAUSS A, SAUER P, STIEHL A, et al. Evaluation of biliary calprotectin as a biomarker in primary sclerosing cholangitis[J]. Medicine, 2016, 95( 17): e3510. DOI: 10.1097/MD.0000000000003510.
    [22]
    SRIKRISHNA G. S100A8 and S100A9: New insights into their roles in malignancy[J]. J Innate Immun, 2012, 4( 1): 31- 40. DOI: 10.1159/000330095.
    [23]
    JAMNONGKAN W, THANAN R, TECHASEN A, et al. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool[J]. Tumour Biol, 2017, 39( 7): 1010428317717655. DOI: 10.1177/1010428317717655.
    [24]
    MANCINELLI R, CUTONE A, ROSA L, et al. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma[J]. Eur J Histochem, 2020, 64( 4): 3156. DOI: 10.4081/ejh.2020.3156.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (227) PDF downloads(35) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return